Psych Vivas · Psychopharmacology — metabolic syndrome and psychotropic monitoring
Metabolic syndrome and psychotropic monitoring — consultant viva
Fellowship viva on metabolic criteria, agent hierarchy, monitoring schedule, mechanisms, metformin/switch evidence and special populations.
On this page
Study tools
Target exams
FRANZCPMRCPsychABPNMD-DNB
Prompt
Examiner cards: ATP III/IDF components; clozapine/olanzapine vs aripiprazole ranking; ADA/APA 4/8/12-week weight; Correll 2009 youth; CATIE metabolic trade-off; H1/5-HT2C; Wu and Jarskog metformin; switch to aripiprazole; keep clozapine in TRS; who owns the bloods.
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect named criteria, hierarchy, schedule numbers, and named trials — not vague “monitor physical health”.[1][7]
References10ShowHide
- [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
- [2]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730
- [3]Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med, 2005.PMID 16172203
- [4]Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
- [5]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
- [6]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
- [7]De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat Rev Endocrinol, 2011.PMID 22009159
- [8]Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis Schizophr Bull, 2013.PMID 22207632
- [9]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
- [10]Alberti KG, Zimmet P, Shaw J Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet Med, 2006.PMID 16681555